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Neurobiology of Disease
The Role of G-Protein Receptor 84 in Experimental
Neuropathic Pain
Louise S.C. Nicol,1 JohnM. Dawes,2 Federica La Russa,1 Athanasios Didangelos,1 XAnna K. Clark,1 Clive Gentry,1
John Grist,1 John B. Davies,3 Marzia Malcangio,1 and XStephen B. McMahon1
1Wolfson Centre for Age-Related Disease, King’s College London, London, SE1 1UL, United Kingdom, 2Nuffield Department of Clinical Neurosciences,
University of Oxford, John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom, and 3GlaxoSmithKline, Harlow, CM19 5AW, United Kingdom
G-protein receptor 84 (GPR84) is an orphan receptor that is inducedmarkedly inmonocytes/macrophages andmicroglia during inflam-
mation, but its pathophysiological function is unknown. Here, we investigate the role of GPR84 in a murine model of traumatic nerve
injury. Naive GPR84 knock-out (KO) mice exhibited normal behavioral responses to acute noxious stimuli, but subsequent to partial
sciatic nerve ligation (PNL),KOsdidnot developmechanical or thermal hypersensitivity, in contrast towild-type (WT) littermates.Nerve
injury increased ionized calciumbinding adaptermolecule 1 (Iba1) and phosphorylated p38MAPK immunoreactivity in the dorsal horn
and Iba1 and cluster of differentiation 45 expression in the sciatic nerve, with no difference between genotypes. PCR array analysis
revealed thatGpr84 expressionwas upregulated in the spinal cord and sciatic nerve ofWTmice. In addition, the expression of arginase-1,
a marker for anti-inflammatory macrophages, was upregulated in KO sciatic nerve. Based on this evidence, we investigated whether
peripheral macrophages behave differently in the absence of GPR84. We found that lipopolysaccharide-stimulated KO macrophages
exhibited attenuated expression of several proinflammatory mediators, including IL-1, IL-6, and TNF-. Forskolin-stimulated KO
macrophages also showed greater cAMP induction, a second messenger associated with immunosuppression. In summary, our results
demonstrate that GPR84 is a proinflammatory receptor that contributes to nociceptive signaling via the modulation of macrophages,
whereas in its absence the response of these cells to an inflammatory insult is impaired.
Key words: cytokine; G-protein linked receptors; inflammation; macrophage; microglia; neuropathic pain
Introduction
Although there has been significant progress in the understand-
ing of pain processes, chronic pain remains an area of consider-
able unmet medical need because of limited number and efficacy
of treatments. Therefore, the search for new and more effective
treatment continues. It has emerged that the immune system and
its related molecules are important players in persistent pain and
thus possess immense therapeutic potential. Unsurprisingly, the
identification of novel immune-related targets has attracted the
interest of many. Here we have explored the role of an orphan
receptor, G-protein receptor 84 (GPR84), that was identified
originally using an expressed sequence tag data mining strategy
(Wittenberger et al., 2001). GPR84 consists of a generic heptahe-
lical structure and is thought to belong to the rhodopsin super-
family, with little similarity to other known receptors. Expression
analysis revealed that human and mouse GPR84 mRNA is found
predominantly in hematopoietic tissues, including bone marrow,
lung, spleen, and lymphnode (Wittenberger et al., 2001;Wang et al.,
2006). Its expression is restricted to peripheral immune cells and
microglia in the CNS, and it is upregulated via appropriate immu-
nostimulation [such as lipopolysaccharide (LPS) or TNF exposure;
Wang et al., 2006; Bouchard et al., 2007; Lattin et al., 2008].
Although GPR84 was discovered well over a decade ago, very
little is known about its functional role. So far, functional analy-
ses have suggested that it is a free fatty acid (FFA) sensing GPCR
that couples primarily to the Bordetella pertussis toxin-sensitive
Gi/o pathway (Wang et al., 2006; Suzuki et al., 2013). In partic-
ular, FFAs with medium carbon chain lengths of C9–C14 have
shown efficacy in heterologous expression systems, but the en-
dogenous ligand has yet to be identified. Several groups have
postulated an immunomodulatory role that coincides with its
restricted immune cell expression. It has been reported that
GPR84 mediates chemotaxis and the release of TNF and IL-12
from macrophages and IL-8/chemokine ligand 8 from granulo-
cytes (Wang et al., 2006; Suzuki et al., 2013). IL-12 plays a key role
in promoting T-helper 1 (Th1)-driven immunity while inhibit-
ing Th2 anti-inflammatory responses. Therefore, it is plausible
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that GPR84 is involved in regulating Th1 differentiation to pro-
mote an inflammatory response. Interestingly, these findings
were consistent with augmented Th2 cytokine production in
GPR84 null T cells (Venkataraman and Kuo, 2005). Further-
more, Bouchard et al. (2007) demonstrated that GPR84mRNA is
strikingly upregulated in cortical and spinal microglia in a model
of endotoxemia and experimental autoimmune encephalomyeli-
tis (EAE). Together, these findings are suggestive of an immuno-
regulatory and neuroinflammatory function.
Despite a lack of evidence of a role in nociceptive transmission,
the upregulation of GPR84 mRNA has been observed in clinically
relevant animal models of diabesity and EAE, which feature pain-
associated pathologies (Bouchard et al., 2007; Tomlinson and Gar-
diner, 2008; Nagasaki et al., 2012; Khan et al., 2014). Moreover, its
role in promoting a proinflammatory immune response and the
release of cytokines, many of which can directly or indirectly mod-
ulate pain pathways (Kiguchi et al., 2012), supports the notion that
GPR84 is a promising new target in the field.
Here we used GPR84 null mice to examine pain behaviors in a
model of peripheral nerve injury. We focused on changes in the
response of spinal microglia and peripheral macrophages with
the aim of elucidating the contribution of GPR84 to neuropathic
pain states.
Materials andMethods
Experimental animals.GPR84 (GenBank accession numberNM_030720,
Ensembl identification number ENSMUSG00000063234) KOmice were
provided by Deltagen under a GlaxoSmithKline license agreement. Tar-
geting replaced 257 bp of coding sequence with an IRES–LacZ–poly(A)
expression cassette and a positive selection cassette that contains the
neomycin phosphotransferase gene driven by the PGK promoter (Neo).
The insertion of the LacZ IRESLacZ introduces a premature translational
stop signal that deletes the first three predicted transmembrane domain
sequences. Disruption of the GPR84 gene was confirmed using PCR and
standard agarose gel electrophoresis using the following primers: gene
specific (endogenous), 5-ACAGCTCAGATGCCAACTTCTCCTG-3;
gene specific (targeted, endogenous), 5-TCCTAGAGCAATGAGACA-
GAGGGTG-3; and Neo (targeted), 5- GACGAGTTCTTCTGAGG
GGATCGATC-3.
Mice forming the initial breeding pairs were supplied by GlaxoSmith-
Kline, which consisted of heterozygous (HET) F1 offspring fromWTand
KObreeding. HET pairs were bred in-house from 8weeks old to produce
litters of mixed genotypes according to Mendelian genetics. Mice were
housed individually or in groups in standard environmental conditions
(12 h light/dark cycle) with ad libitum access to food and water. Experi-
ments were conducted in a blocked design on randomly selected, mixed
sex- and age-matched WT and KO mice weighing 20–30 g (7–14 weeks
old). HETs were only used for breeding. Animal husbandry and experi-
ments were performed in a nonsterile housing environment in accor-
dance with the United Kingdom Animals (Scientific Procedures) Act
1986. For all studies, the experimenter was blinded to genotype and
treatment.
Mechanical withdrawal threshold. Static mechanical thresholds of alert
and unrestrained mice were examined via von Frey hair application
(0.008–1 g; Touch Test; Stoelting) to the plantar surface of the hindpaw
using the “up–down”method (Chaplan et al., 1994). Before testing,mice
were acclimatized individually for 1 h in acrylic testing cubicles (8 5
10 cm) on an elevated wire mesh floor to enable access to the lateral paw
surface. Placement in testing cubicles was selected at random for each
testing day. Briefly, calibrated von Frey hairs were applied in an alternate
manner to the left or right hindpaw, starting with the 0.6 g filament. The
flexible nylon hair was applied so that the fiber was bent for 3 s or until a
paw-withdrawal reflex occurred. A positive withdrawal response is fol-
lowed by a lower force hair and vice versa for a negative response until a
change in behavior occurs. Using this up–down sequence, four subse-
quent hairs were assessed and the 50%paw-withdrawal threshold (PWT)
was calculated according to the method described by Dixon (1980).
Paw pressure. Noxious mechanical thresholds were examined in the
hindpaws of lightly restrained alert mice via an Analgesy-Meter (7200;
Ugo Basile; Randall and Selitto, 1957). The plantar surface of the hind-
paw was placed on a pedestal with a probe resting on the dorsal surface.
Increasing pressure was applied via the probe up to a maximum of 120 g
to prevent tissue damage. The nociceptive threshold was taken as the
force at which the mouse responded.
Thermal withdrawal threshold. Thermal thresholds in unrestrained
and alert mice were determined with the Hargreaves method using the
plantar test (7370; Ugo Basile; Hargreaves et al., 1988). Before testing,
mice were acclimatized for 1 h in individual acrylic testing cubicles (8
5 10 cm) on a glass plate. Placement in testing cubicles was selected at
random for each testing day. An infrared light source of an arbitrary
intensity of 30 [calibrated to elicit a paw-withdrawal latency of 10–15 s in
naivemice]was directed onto the plantar surface of the hindpaw through
the glass plate. The left and right paws were tested alternately, and with-
drawal reflex responses were recorded for each paw in seconds on three
separate occasions with at least 2 min between stimuli. Each test had a
maximum latency of 23 s to prevent tissue damage.
Tail immersion withdrawal. Thermal thresholds of the tails of lightly
restrained mice were examined via the tail immersion-withdrawal test
(Mogil et al., 1999). The distal third of the tail was immersed directly in
water at a set temperature of either 49°C or 52  0.2°C (Grant SUB14;
Grant Instruments). The thermal withdrawal latency was recorded to the
nearest 0.01 s as a characteristic vigorous tail reflex response. A maxi-
mum latency of 20 and 10 s was permitted at temperatures of 49°C and
52°C, respectively, to prevent tissue damage.
Hot plate.Noxious thermal thresholds of the hindpawswere examined
via the hot plate test (Eddy and Leimbach, 1953) using an incremental
hot/cold plate (IITC Life Sciences) set at a temperature of 49 0.2°C.Mice
were placed on the hot plate in a 10-cm-diameter acrylic testing box; jump-
ing, licking, or stamping reflex responseswere recorded to the nearest 0.01 s.
Amaximum latency of 20 s was permitted to prevent tissue damage.
Cold plate. Noxious cold thresholds of the hindpaws of lightly re-
strained mice were examined using an incremental hot/cold plate (IITC
Life Sciences) set at a temperature of 10  0.2°C. Each paw was tested
separately by placing the plantar surface on the plate. The latency to
withdraw was recorded to the nearest 0.01 s. A 20 s cutoff was imple-
mented to prevent tissue damage.
Locomotor function. Balance and coordination were examined via the
locomotor test. Mice were placed on a RotaRod accelerating from 2 to 40
rpm over a period of 300 s (7650; Ugo Basile). Mice were initially trained
before testing, and unsuccessful test runs were performed again. None
remained on the apparatus after 100 s.
Neuropathic pain model. Animals were anesthetized with 2–3% isoflu-
rane (Abbott Animal Health), and the left hindpaw was secured, shaved,
and sterilized. The sciatic nerve was carefully exposed and isolated from
neighboring connective tissue via a small incision midway of the left
thigh. At a site within close proximity to the trochanter, distal to the
posterior biceps semitendinosus nerve branch, a 5-0 Vicryl suture (Ethi-
con) was inserted into the nerve and ligated so that one-third to one-half
of the nerve was held tightly within the ligature, as described previously
(Seltzer et al., 1990). In sham operated mice, the same procedure was
performed except that the nerve was not ligated. Mechanical (von Frey)
and thermal (Hargreaves) withdrawal thresholds were examined on 3–5
separate days before surgery and on days 4, 7, 11, 14, 18, and 21 after
surgery.
Tissue preparation and immunohistochemistry. On days 7 or 21 after
surgery, mice were terminally anesthetized with sodium pentobarbital
(0.2 g/ml, i.p.; Euthatal; Merial Animal Health) and perfused transcardi-
ally with a 0.9% saline and 0.1% heparin solution (Leo Laboratories),
followed by fixation with 4% paraformaldehyde (PFA; VWR) in 0.1 M
phosphate buffer. Lumbar spinal cord and sciatic nerve were dissected
and postfixed for 2 h in PFA and cryoprotected in a 20% sucrose/0.1 M
PBS (VWR) for a minimum of 3 d at 4°C. Subsequently, tissue was
embedded in Optimum Cutting Temperature medium (VWR), snap
frozen with liquid nitrogen, and stored at 80°C. Before embedding,
sutures were removed from injured sciatic nerves. Transverse spinal cord
sections of the L4 and L5 lumbar region and longitudinal nerve sections
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were cut on the cryostat at 20 m thickness and subsequently thaw
mounted onto Superfrost Plus microscope slides (VWR). After drying,
7 d post-PNL or sham surgery spinal cord sections were incubated over-
night with primary antibody solution for phosphorylated p38 MAPK
(p-p38; rabbit anti-p-p38; 1:100; Sigma) and visualized with extrAvidin–
FITC after two stages of signal amplification with avidin–biotin complex
(Vector Laboratories) and biotinyl tyramide (PerkinElmer Life and An-
alytical Sciences) as shown previously (Clark et al., 2006). The sections
were then incubated overnight with the second primary antibody, raised
against rabbit anti-Iba1 (1:1000; Wako Chemicals). Spinal cord (21 d)
and sciatic nerve sectionswere incubatedwith Iba1 and rat anti-cluster of
differentiation 45 (CD45; 1:500; R&D Systems). Subsequently, sections
were incubated with the appropriate secondary antibody solution for 2 h
(1:1000; IgG-conjugated Alexa Fluor 488 or 546; Invitrogen). All anti-
bodies were prepared in PBS supplemented with 0.1% Triton X-100
(VWR) and 0.2% sodium azide (Sigma). Slides were coverslipped with
VectashieldMountingMedium containing DAPI (Vector Laboratories),
and images were captured using a Axioplan microscope (Zeiss).
Quantification of immunoreactivity. In spinal cord sections, analysis of
p-p38 and Iba1 immunoreactivity was performed by counting the num-
ber of positive profiles within three fixed 4  104 m2 boxes in the
lateral, central, and medial areas of the dorsal horn, using the nuclear
marker DAPI to assist in determining positive cells, as described previ-
ously (Clark et al., 2007). A mean value was obtained for both the ipsi-
lateral and contralateral dorsal horns. In sciatic nerve sections, two boxes
of 4 104m2 area were placed proximal to the nerve lesion and 1mm
from the epicenter. For analysis of contralateral nerve sections, two boxes
were placed randomly along the nerve. The number of Iba1- and CD45-
positive cells was counted within the boxes, and a mean value was ob-
tained. Again DAPI was used to assist in the identification of positive cell
profiles. Throughout the quantification process, a minimum of three
sections per animal was assessed, and scoring was performed blind to
genotype and treatment.
Bio-Gel elicited peritoneal macrophage cell culture and stimulation.
AdultGPR84WTandKOmicewere given an intraperitoneal injection (1
ml) of Bio-Gel P-100 2% polyacrylamide beads (Bio-Rad). Four days
later, mice were culled via cervical dislocation, and the layer of skin
covering the peritoneumwas wiped with 70% ethanol. A total volume of
20 ml of sterile cold PBS (Invitrogen) containing EDTA (3 mM; Invitro-
gen) was injected into the peritoneal cavity using a 25 gauge needle. After
gentle massaging, the buffer was retrieved in 14 ml Falcon tubes, filtered
to remove the polyacrylamide beads, and spun to obtain a pellet. Cells
were then resuspended and plated in cAMP-Screen Direct precoated
96-well assay plates (Invitrogen) at a density of 1.5 105 cells perwell for
the assessment of cAMP production. For mRNA analysis, peritoneal
macrophages were collected in the same way as described above without
previous administration of Bio-Gel beads and were plated in six-well
plates at a density of 2 106 cells per well for RNA extraction.
Cells were maintained in DMEM with 10% fetal bovine serum (FBS)
and 1% penicillin–streptomycin (Invitrogen, Sigma) and incubated at
37°C (5% CO2/95% O2). Two hours later, cells were washed, and the
mediumwas replaced. Twenty four hours later, themediumwas replaced
with FBS-free medium for 2 h, followed by 3 h of LPS stimulation (1
g/ml; Sigma). The culture medium of control wells was replaced with
fresh FBS-free medium without subsequent stimulation.
Bone marrow-derived macrophage cell culture and stimulation. Adult
GPR84 WT and KOmice were culled via cervical dislocation. The lower
bodywas sterilizedwith 70% ethanol, and the skin of both hindlimbswas
removed. Muscle and fat tissue surrounding the femur, tibia, and fibula
was removed carefully, and the bones were collected in ice-cold DMEM.
Subsequently, the bones were flushed with 5–10 ml of cold PBS and the
cells were collected, resuspended and plated in DMEM containing 10%
FBS, 1% penicillin–streptomycin (Sigma) andmacrophage-colony stim-
ulating factor (Peprotech). Cultures were maintained for 1 week at 37°C
(5% CO2/95% O2). After 1 week, cells were incubated with non-
enzymatic cell dissociation buffer (Millipore) at 37°C for 10 min and
were scraped carefully and replated in cAMP-Screen Direct precoated
96-well assay plates (Invitrogen) at a density of 1.0 105 cells per well to
assess cAMP production. Twenty-four hours later, the medium was re-
placed with FBS-free medium for 2 h, followed by 3 h of LPS stimulation
(1g/ml; Sigma). The culturemediumof control wells was replacedwith
fresh FBS-free medium without subsequent stimulation.
RNA extraction and cDNA synthesis.Ondays 7 or 21 after PNL or sham
surgery, mice were terminally anesthetized with sodium pentobarbital
(0.2 g/ml, i.p.; Euthatal;Merial AnimalHealth). The lumbar region of the
spinal cord was dissected, separated into the ipsilateral and contralateral
sides, and placed into separate RNase free 1.5 ml Eppendorf tubes. The
ipsilateral and contralateral sciatic nerves of 1 cm in length were also
collected and stored. The collected tissue was immediately snap frozen in
liquid nitrogen and stored at80°C for additional processing. RNA was
extracted via homogenizing the tissue samples using a hybrid method of
phenol extraction (TRIzol; Invitrogen) and column purification
(RNeasy; Qiagen). After purification, the RNA was eluted using RNase-
freewater, and its concentration andpuritywere estimated using aNano-
Drop ND-100 Spectrophotometer (Thermo Fisher Scientific). All 260:
280 absorbance ratios were in the range of 1.96–2.15. During RNA
isolation, samples were also treated with DNase (Qiagen) to prevent
genomic contamination. RNA integrity was confirmed with a RNA 6000
Nano Chip Bioanalyzer (Agilent Technologies). cDNAwas subsequently
synthesized from RNA using the SuperScript II reverse transcriptase kit
(Invitrogen) according to the guidelines of the manufacturer.
After LPS stimulation of cultured peritoneal macrophages, cells were
homogenized by removing the media and directly adding TRIzol to the
well. RNA was extracted, and cDNA was synthesized as described above.
Taqman array setup and quantitative real-time PCR. Taqman PCR
array cards were custom designed using the Applied Biosystems website
(http://www.appliedbiosystems.com). The cards use micro-fluidic tech-
nology, comprising 384 wells and four sets of 96 different primer/probe
pairs against specific genes within the mouse genome, including four
reference genes: glyceraldehyde-3-phosphate dehydrogenase, 18S ribo-
somal RNA, -actin, and hypoxanthine phosphoribosyltransferase. Spi-
nal cord and sciatic nerve cDNA samples from 7 and 21 d post-PNL or
sham surgery and control or LPS-stimulated macrophages were diluted
and added in a 1:1 ratio to Taqman universal PCR master mix (Applied
Biosystems; contains DNATaq polymerase and dNTPs). DNase-free wa-
ter was added to the sample mix, producing a final [cDNA] of 2 ng/l in
a total volume of 100l. The samplemix was loaded into the appropriate
port, and the cards were centrifuged so that 1l was channeled into each
well. Cards were then sealed and placed into a 7900 HT Fast Real-Time
PCR system (Applied Biosystems), and cDNA samples underwent 40
amplification cycles. For each sample, changes in gene expression was
calculated using the Delta Delta cycling time (CT) method as de-
scribed previously (Schmittgen and Livak, 2008) and normalized against
four reference genes with the R package ReadPCR and NormqPCR (Per-
kins et al., 2012). Transcripts with undetermined values in50% of the
samples were assigned an average default CT value of 38. When this
occurred in both PNL and sham or control and LPS-stimulated sample
groups, no fold change (FC) value was calculated (FC 	 treatment/
control). Transcripts that were undetermined in 
50% of samples ob-
tained an average CT value based on the remaining data values.
cAMP-screen direct chemiluminescent ELISA.GPR84WT and KO Bio-
Gel elicited peritoneal macrophages (B-GEPMs) or bone marrow-
derived macrophages (BMDMs) were harvested as described above and
plated in cAMP-Screen Direct precoated 96-well assay plates (Invitro-
gen) at a density of 1.0–1.5 105 cells per well. Two hours later, the cells
were washed, replenished with fresh DMEM (Invitrogen), and left over-
night to settle. All cell stimulation protocols were performed 24 h later
and done in FBS-free DMEM (Sigma) at 37°C. WT and KO cells were
incubated for 20 min with 50 M forskolin (FSK; R&D Systems), and
control wells were incubated in fresh media containing 0.002% ethanol.
Cells that underwent LPS stimulation were incubated with 1 g/ml LPS
(Sigma) for 3 h before FSK stimulation. After the stimulation procedure,
the assay was terminated, and samples were processed according to the
guide of the manufacturer (Invitrogen). Subsequently, the luminescence
signal for each well was measured using a standard luminometer (1
s/well), and the cAMP concentration was calculated via extrapolation
from a standard curve.
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Data and statistical analysis. All data were analyzed using SigmaPlot
12.3 and SigmaStat software. For single comparisons between two
groups, a paired Student’s t test was applied (behavioral data). For mul-
tiple comparisons, one-way (immunohistochemical data) or two-way
(behavioral data) ANOVA was used, followed by Student–Newman–
Keuls (SNK) post hoc test to determine individual group differences. For
the Taqman mouse PCR array card data, two-sided Welch’s t tests were
run in the R program on the CT values. The p values were adjusted
using the false discovery rate (FDR) to correct for multiple hypothesis
testing, as described previously (Benjamini et al., 2001). Nonparametric
tests were applied when the data were not normally distributed, and a
Kruskal–Wallis one-way ANOVA on ranks was used, followed by
Tukey’s method. In all cases, the data are presented as the mean SEM,
and p
 0.05 was set as the statistical significance level.
Results
GPR84 KOmice have normal acute pain thresholds, but
neuropathic pain hypersensitivity is absent
We first investigated whether GPR84 function affects acute pain,
and WT and KO mice were assessed behaviorally after acute pe-
ripheral application of a range ofmechanical and thermal stimuli
(Fig. 1). KO mice exhibited normal thermal pain thresholds to
varying levels of intensity applied to the hindpaw or tail (Fig.
1A–E) compared with WT littermates. KO mice also exhibited
normal mechanical thresholds of low and high intensity (Fig.
1F,G) and showed no deficits in locomotor function (Fig. 1H).
To determine whether GPR84 plays a role in chronic pain, we
tested mechanical and thermal thresholds of WT and KO mice
after PNL or sham surgery. It is well established that peripheral
nerve injury results in the development of mechanical and ther-
mal hypersensitivity in the ipsilateral hindpaw. Accordingly,
nerve injuredWTmice showed an average reduction of 68.8% in
mechanical thresholds from baseline that was present on day 4
and persisted until day 21 (Fig. 2A). WT mice also exhibited an
increase in thermal sensitivity, with an average reduction of
25.4% in thresholds from baseline over the 21 testing days (Fig.
2B). In contrast, nerve injured KOmice did not developmechan-
ical (Fig. 2C) or thermal (Fig. 2D) hypersensitivity over the 21
testing days, and thresholds did not drop from baseline or differ
from KO sham controls at any point. For clarity, genotype data
are presented separately, but statistical analysis was conducted on
all four experimental groups. Together, these data indicate that
GPR84 deletion impairs the development and persistence of neu-
ropathic pain hypersensitivity, but under normal physiological
conditions, GPR84 is not involved in acute nociception.
GPR84 does not modulate microglial responses under
neuropathic conditions
Sincemicroglia play a key role in the initiation of pain-associated
behaviors andGPR84 is expressed exclusively on these cells in the
Figure1. GPR84 KOmice display normal acute pain responses and locomotor ability. To assess acute nociception in naive GPR84WT and KOmice, responses to a range of thermal andmechanical
acute pain tests were compared. There were no significant differences between genotypes in the temperature threshold tests [Hargreaves (A); tail immersion withdrawal at 49°C (B) or 52°C (C);
hotplate at 49°C (D); cold plate at 10°C (E)] ormechanical threshold tests [von Frey (F ); pawpressure (G)]. GPR84KOmice alsodisplayednormal locomotor functionusing theRotaRodapparatus (H ).
Data are presented as mean SEM. p 0.05, independent Student’s t test, n	 8–14.
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CNS (Bouchard et al., 2007), we examined the microglial pheno-
type to elucidate whether deletion of GPR84 alters nerve injury-
induced microgliosis. Quantification of Iba1 immunoreactivity
at 7 d after PNL revealed that both genotypes showed a 3.2-fold
increase in Iba1-positive cells in the ipsilateral dorsal horn (WT
PNL, 21.1  1.7; KO PNL, 21.6  2.4) compared with sham
controls (WT, 6.6 2.0; KO, 6.7 0.7; Fig. 3A,B). This change
persisted at 21 d after PNL for both genotypes, with a 1.8-fold
increase compared with sham (WT PNL, 9.3  0.7; KO PNL,
11.1 0.8 vs WT, 5.3 0.6; KO, 6.1 0.9; Fig. 3D,E). Notably,
at both time points, KO microglia exhibited typical de-ramified
and amoeboid morphology in response to injury to that seen in
the WT.
We also assessed whether GPR84 deletion affects the activa-
tion ofmicroglial cells as revealed by p-p38MAPK, a key kinase in
nociceptive pathways (Ji and Suter, 2007; Ji et al., 2009). At day 7,
WT and KO mice showed a 3.4- and 4.1-fold increase in p-p38
positive cells, respectively, in the ipsilateral dorsal horn (WT
PNL, 20.4  2.1; KO PNL, 18.6  3.7) compared with sham
controls (WT, 6.0  2.3; KO, 4.5  1.3; Fig. 3A,C), and there
were no significant differences between genotypes. In summary,
GPR84 does not play a role in modulating microglial numbers or
activation via Iba1 and p-p38 markers, respectively, in response
to peripheral neuropathy.
GPR84 activation promotes a proinflammatory
macrophage phenotype
As we found no evidence of an altered microglia response in
association with the KO behavioral phenotype, we sought to ex-
amine the possible contribution of peripheral macrophages.
Macrophages are the key phagocytic immune cell of the PNS and
are also reported to play a role in nerve injury-induced behavioral
hypersensitivity (Myers et al., 1996; Liu et al., 2000; Barclay et al.,
2007). To investigate whether deletion of GPR84 may alter the
peripheral inflammatory response to nerve damage mediated by
infiltrating macrophage cells, longitudinal sciatic nerve sections
containing the injury site were immunostained for Iba1 and
CD45 at 7 d after PNL. Positive cell profiles costained with DAPI
were counted proximal to the lesion site and 1 mm from the
epicenter as illustrated in Figure 4I. Quantification of immuno-
reactivity revealed that, inWT and KOmice, there was a 93.4 and
92.8% increase in Iba1-positive cells, respectively, comparedwith
contralateral controls (WT ipsilateral, 43.0 6.6; KO ipsilateral,
42.8 1.7 vsWT contralateral, 3.1 0.6; KO contralateral, 3.3
0.2; Fig. 4A,B,E,F,J). Similarly, there was an equivalent increase
in CD45 expression in WT (88.5%) and KO (87.0%) mice com-
pared with contralateral controls (WT ipsilateral, 11.1 3.5; KO
ipsilateral, 11.0  1.9 vs WT contralateral, 1.4  0.4; KO con-
tralateral 1.6 0.2; Fig. 4C,D,G,H, J). This confirms that GPR84
Figure 2. Reduced neuropathic pain in GPR84 KOmice. Mechanical (A, C) and thermal (B,D) withdrawal responses of GPR84WT (A, B) and KO (C,D) mice weremeasured before (day 0) and up
to 21 d after PNL or sham surgery. WT mice developed significant mechanical hypersensitivity and showed reduced thermal thresholds compared with sham controls. Mechanical and thermal
hypersensitivity were absent in KOmice and did not differ from sham values at any time. Data are presented asmean SEM. *p
 0.05, **p
 0.01, ***p




 0.001 versus sham control, two-way repeated measure ANOVA with SNK post hoc test, n	 9–12.
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does not play a role in regulating the infiltration of monocytes or
the local proliferation and migration of resident macrophages to
the injury site.
We next wanted to determine whether deletion of GPR84
correlates with an altered nerve injury-induced inflammatory
mediator expression. Here we used high-throughput custom-
made Taqman array cards to profile the transcriptional regula-
tion of a range of immune-related genes (cytokines, chemokines,
and growth factors) in the nerve and spinal cord of WT and KO
mice. We found that a number of genes were differentially regu-
lated between the genotypes (data not shown), several of which
were of particular interest to us, including arginase-1 (Arg-1),
Il-10, and Gpr84 itself. Genes of interest were identified via im-
plementing strict threshold criteria. This included an FC thresh-
old of 2 so that genes with marginal expression changes as a
result of noise were excluded. An FC ratio (KO FC/WT FC) of
1.5 was also set to omit genes that were not transcriptionally
regulated by GPR84. Together, these criteria enabled the identi-
fication of genes that were considerably differentially regulated
between genotypes.
In agreement with our hypothesis that GPR84 is a valid target
in chronic pain, its expression was upregulated in the sciatic
nerve and spinal cord of neuropathic WT mice at days 7 and 21
compared with sham controls; however, this was only significant
Figure 3. Nerve injury-inducedmicrogliosis is normal in GPR84 KOmice. At 7 d (A–C) and 21 d (D, E) after PNL, there was a significant increase in Iba1- and p-p38-positive cells in the ipsilateral
dorsal horn of GPR84WT (WT PNL) and KO (KO PNL)mice comparedwith control sham groups (WTS and KOS) (A,D; quantified inB, C, E). There were no significant differences between genotypes.
Data are presented as mean SEM. **p
 0.01, ***p
 0.001 versus contralateral; ###p
 0.001 versus sham, one-way ANOVA with SNK post hoc test, n	 4–6. Scale bar, 200m.
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in the nerve at day 7 (36.7 9.4; Fig. 4K). Interestingly, Arg-1, a
marker associated specifically with alternatively activatedmacro-
phages, was among the top upregulated genes in the sciatic nerves
of KO mice 7 d after PNL compared with WT controls (WT,
3.8 0.4; KO, 21.2 5.6; Fig. 4L). Furthermore, the expression
of the anti-inflammatory cytokine Il-10wasmore greatly induced
in the injured nerves of KOs thanWTs (WT, 1.7 0.2; KO, 6.9
3.2; Fig. 4M). These results indicate that, although the number of
monocytes/macrophages in the injured sciatic nerve does not
differ between genotypes, it is possible that GPR84 regulates the
activation state of these cells instead. In addition, GPR84 mRNA
upregulation was greater in the nerve than the spinal cord of WT
mice, and there were no differences in microgliosis between ge-
notypes, suggesting that GPR84-mediated signalingmay bemore
important in the periphery. Based on this evidence and the doc-
umented role of macrophages in models of inflammation and
Figure 4. After injury, GPR84 KOmice exhibit normal peripheralmacrophage recruitment but elevated anti-inflammatorymarker expression in the sciatic nerve. Therewas a significant increase
in Iba1- and CD45-positive cells in the ipsilateral (ipsi) sciatic nerve 7 d after PNL in GPR84 WT (E, G) and KO (F, H ) mice compared with contralateral (contra) controls (A, C and B, D, respectively;
quantified in J ). There were no significant differences between genotypes. Longitudinal sections of nerve were counted, proximal to the nerve injury and 1mm from the epicenter as illustrated in
I. Scale bar, 1000m.Data are presented asmean SEM. *p
0.05, ***p
0.001 versus contralateral, one-wayANOVAwith SNKpost hoc test,n	3. Scale bar, 200m.Transcriptional analysis
revealed an induction of GPR84 expression in WT sciatic nerve and spinal cord at 7 and 21 d after PNL compared with sham (K ). In the sciatic nerve of KO mice 7 d after PNL, there was a greater
induction of Arg-1 (L) and Il-10 (M ) comparedwithWT littermates. Changes inmRNA expression are normalized to reference genes. Data are presented asmean SEM. **p
 0.01 versus sham;
##p
 0.01 versus WT PNL, t test with FDR for multiple testing correction, n	 4.
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traumatic nerve injury-induced pain, we then tested whether
GPR84 deletion impairs the ability of macrophages to launch an
inflammatory response.
As before, we used custom-made Taqman array cards to ana-
lyze the relative expression of a range of mediators in peritoneal
macrophages after a potent immune stimulus. LPS stimulation of
cultured macrophages increases cytokine synthesis in a Toll-like
receptor-4 (TLR4) dependent manner, which is a key molecule
involved in generating responses to pathogen-associated molec-
ular patterns (PAMPs). PAMPs, such as HSP60 and HSP70, ne-
crotic cells, and components of the extracellular matrix (ECM)
are abundantly found at sites of injury. These factors activate TLR
signaling and nuclear factor-B (NF-B)-mediated transcription
of many proinflammatory mediators (Nguyen et al., 2002; Willis
et al., 2005). Accordingly, application of LPS to the injured sciatic
nerve enhances the recruitment of macrophages and the process
of Wallerian degeneration (Boivin et al., 2007), whereas deletion
of TLR4 attenuates pain-associated behaviors (Tanga et al.,
2005). Based on this evidence, we believe that our in vitro para-
digm was a relevant representation of the in vivo situation and
would enable us to examine genotypic-dependent differences in
the macrophage response.
Among the 92 immune-related genes tested after LPS expo-
sure, several proinflammatory mediators associated with pro-
nociceptive signaling showed a greater upregulation in WT than
KO macrophages. These were IL-1 (WT, 155.4  51.3; KO,
123.8 50), IL-6 (WT, 570.4 67.2; KO, 198.6 35.6), Tnf-
(WT, 74.5  7.6; KO, 51.5  7.5), prostaglandin E synthase 2
(Ptges2; WT, 408.2  80.6; KO, 237.1  99.4), nitric oxide syn-
thase 2 (Nos2; WT, 85.8  22.7; KO, 26.3  7.5), Il-12b (WT,
81.3  19.3; KO, 29.1  7.9), chemokine (C-C motif) ligand 2
(Ccl2; WT, 37.9 6.7; KO, 18.3 3.1), and Ccl3 (WT, 101.4
9.3; KO, 47.3  5.7). Conversely, anti-inflammatory Il-10 was
more greatly induced in the KO (WT, 27.2  20.9; KO, 44.0 
37.1; Fig. 5A,B). LPS stimulation also increasedGpr84 expression
in WT cells (3.3  0.7) and was undetectable in the KO (Fig.
5A,B). These findings suggest that GPR84 regulates the release of
a subset of proinflammatory mediators under neuropathic con-
ditions. Therefore, it is plausible that the painless KO phenotype
is attributable to a reduced capacity of peripheralmacrophages to
launch an inflammatory response.
In light of our transcriptional data, we wanted to ascertain
whether KOmacrophages are immunosuppressed by examining
the synthesis of cAMP under FSK- and LPS-stimulated condi-
Figure 5. GPR84 KOmacrophages exhibit an attenuated response to LPS stimulation and elevated levels of cAMP. The heat map (A) displays LPS-induced transcriptional changes of a subset of
mediators in peritonealmacrophages. In response to 3 h LPS stimulation (1g/ml) therewas a greater upregulation of a range ofmediators inWT thanKO cells. Transcripts of interest (Gpr84, Il-1,
Il-6, Tnf-, Ptges2, Nos2, Il-12b, Ccl2, and Ccl3) are presented separately (B). Changes inmRNA expression are normalized to reference genes and are relative to control, which is presented as an FC
(FC	 LPS/control). Data are presented asmean SEM. *p
 0.05, **p
 0.01 versusWT, t test, n	 4. GPR84 KO B-GEPMs and BMDMs exhibited greater FSK-induced cAMP levels thanWT cells
under unstimulated and LPS-stimulated (3 h; 1g/ml) conditions (C). Data are presented asmean SEM. **p
 0.01, ***p
 0.001 versus appropriate control, Kruskal-Wallis one-way ANOVA
on ranks with Tukey’s test, n	 4–6.
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tions. Elevated intracellular cAMP has been shown to suppress
innate immune functions, such as phagocytosis, microbe killing,
and production of proinflammatory mediators, but promote the
release of anti-inflammatory mediators (Bourne et al., 1974; Ser-
ezani et al., 2008; Peters-Golden, 2009). We demonstrated that,
in two separate populations of macrophages (B-GEPMs and
BMDMs), KO cells generated greater levels of intracellular cAMP
than WT cells compared with control (B-GEPMs WT, 121.2 
6.4 fmol/ml vsKO, 342.5 37.9 fmol/ml; BMDMsWT, 1960.3
559.8 fmol/ml vs KO, 6995.1  5225.3 fmol/ml; Fig. 5C). This
intriguing greater capacity of KO macrophages to synthesize
cAMP was also maintained under LPS-stimulated conditions,
which is known to reduce cAMP production (BMDMs: WT,
2965.9  1425.3 fmol/ml; KO, 6791.5  3615.1 fmol/ml; Fig.
5C). In accordancewith the literature, these findings support that
GPR84 is coupled to the inhibitory Gi/o family of G-proteins
(Wang et al., 2006) and is essential for downregulating cAMP in
peripheral macrophages to promote a proinflammatory response.
Discussion
To the best of our knowledge, this is the first study to demonstrate
a critical role of GPR84 in experimental neuropathic pain. Con-
sistent with this observation, GPR84 mRNA expression was in-
creased in the sciatic nerve and spinal cord after PNL, and its
deletion abolished the associatedmechanical and thermal behav-
ioral hypersensitivity in mice. Given that GPR84 is expressed
selectively in immune cells (Wang et al., 2006; Bouchard et al.,
2007), we studied microglia and macrophage responses to neu-
ropathy in the presence and absence of this receptor. Interest-
ingly, we did not detect any differences in spinal microglial
responses or macrophage numbers in the sciatic nerve between
genotypes. However, despite no deficit in macrophage recruit-
ment, we observed a striking transcriptional upregulation of the
anti-inflammatory macrophage marker Arg-1 and cytokine Il-10
in injured KO nerves compared with WT controls.
Arg-1 is upregulated in alternatively activated macrophages
and metabolizes L-arginine into L-ornithine and urea. Due to its
higher affinity for arginine, it outcompetes inducible NOS
(iNOS), whichmetabolizes L-arginine in classically activated cells
(Kreider et al., 2007). Subsequently, ornithine amino-transferase
synthesizes proline from ornithine, a substrate crucial in collagen
production, whilst ornithine decarboxylase generates poly-
amines that are involved in cellular proliferation. Together, these
pathways contribute to growth, differentiation, and ECM forma-
tion. Thus, alternatively activated macrophages are involved in
functions related to host defense, repair/wound healing and the
dampening down of harmful inflammation. In contrast, classi-
cally activated macrophages are associated with an upregulation
of iNOS and the production of NO and L-citrulline. Successive
downstreampathways result in the production of reactive oxygen
species, which provide host protection against bacteria, protozoa,
and viruses (Mosser and Edwards, 2008). As ARG-1 and iNOS
compete for the same substrate (L-arginine), the macrophage re-
sponse is tightly regulated and highly dependent on external cues,
such as the stimulus encountered and the microenvironment. In
terms of both phenotype and function, macrophages possess re-
markable heterogeneity. Thus, it is generally believed that mac-
rophage activation encompasses a spectrum of phenotypes that
are not limited to discrete subpopulations (Mosser and Edwards,
2008; Murray and Wynn, 2011).
The high expression of Gpr84 in the nerve along with the
striking injury-induced upregulation of Arg-1 in the KO pro-
vided a strong rationale to examine peripheralmacrophages. This
was on the basis that Arg-1 is exclusively expressed by macro-
phages in the injured nerve (Ydens et al., 2012) and is a specific
marker associated with alternative activation of these cells, as
discussed above. In addition, we found no evidence of an altered
microglia response in the KO and observed greater LPS-induced
Gpr84 expression in WT cultured macrophages than microglia
(data not shown). On closer examination, we found that KO
macrophages exhibited attenuated LPS-induced expression of
several well documented proinflammatory mediators, particu-
larly Il-1, Il-6,Tnf-,Ptges2,Nos2, Il-12b,Ccl2, andCcl3 (Austin
andMoalem-Taylor, 2010; Kiguchi et al., 2012), while showing a
greater induction of anti-inflammatory Il-10 expression.We also
observed greater intracellular FSK-induced cAMP production in
two populations of peripheral KOmacrophages thanWT. cAMP
is upstream of ARG-1 activation, and elevated levels are associ-
atedwith a broad range of immunosuppressive functions, includ-
ing the downregulation of proinflammatory mediators and the
upregulation of anti-inflammatory mediators, as well as a reduc-
tion in phagocytic activity (Bourne et al., 1974; Aronoff et al.,
2005; Serezani et al., 2008; Peters-Golden, 2009;Wall et al., 2009).
In light of this evidence, we postulate that, under pathological
conditions, the ability of KO macrophages to release a subset of
mediators in response to an inflammatory insult is compromised,
resulting in diminished pain behaviors. We propose that GPR84
is a proinflammatory receptor that breaks intrinsic inhibitory
mechanisms by suppressing intracellular cAMP through a Gi/o-
coupled signaling pathway. This results in the release of pro-
nociceptive mediators that directly and/or indirectly contribute
to the development of peripheral and central sensitization.
Considering that GPR84mRNA in the nerve was significantly
upregulated at day 7 and to a lesser extent at day 21 in correlation
with IL-10 and Arg-1 expression, the persistent absence of pain
behaviors suggests that itmay bemore important in the initiation
phase of neuropathic pain. It is well documented that early tran-
scriptional changes are critical in generating long-term changes
in nervous system function. Furthermore, GPR84 is most cer-
tainly not the only molecular player in neuropathic pain, and
there is substantial evidence supporting the notion of several
mechanisms underlying the initiation and maintenance of cen-
tral sensitization (Zimmermann, 2001; Latremoliere and Woolf,
2009).
In animal models of nerve injury, the infiltration of classically
activatedmacrophages (iNOS/ARG) into the sciatic nerve has
been reported as soon as day 1 (Komori et al., 2011). Treatment
with anti-inflammatory cytokines, such as IL-4 or TGF-, atten-
uates pain-associated behaviors via the modulation of macro-
phages. For example, in one study, perineural administration of
TGF- decreasedmacrophage infiltration, which correlated with
reduced behavioral hypersensitivity (Echeverry et al., 2013).
Likewise, the analgesic effects of IL-4 coincided with a shift in the
macrophage phenotype as indicated by upregulated phosphory-
lated signal transducer and activator of transcription 6 and
CD206 expression (Kiguchi et al., 2015). The beneficial effects of
inhibiting classical activation while promoting alternative activa-
tion have also been demonstrated in models of post-incisional
pain and experimental autoimmune neuritis (EAN). One group
showed that local morphine administration into the incised sites
alleviated pain attributable to increased infiltration of wound
healing F4/80 CD206macrophages (Godai et al., 2014). Sim-
ilarly, genetic deletion of TNF- or treatment with compound A,
a plant-derived glucocorticoid receptor ligand, in EANmice cor-
related with decreased severity scores and progression of me-
chanical allodynia. This was found to be a result of increased
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numbers of alternatively activated ED2 (CD163) macrophages
in the sciatic nerve (Zhang et al., 2009, 2012). In agreement with
these studies, our results suggest that the absence of pain behav-
iors in the KO concurred with an alternatively activated macro-
phage phenotype. Unsurprisingly, this notion is not limited to
chronic pain because classically activatedmacrophages have been
implicated in numerous other diseases, such as obesity and dia-
betes (Bastard et al., 2006; Mosser and Edwards, 2008). There-
fore, selective targeting of these cells poses to be a viable option
for the therapeutic treatment of various human diseases.
An interesting observation from our research was the signifi-
cant microgliosis in the spinal cord of injured KO mice, despite
the absence of pain behaviors. GPR84 is expressed exclusively on
spinal microglia, and there is an independent body of evidence
supporting the contribution of these cells to chronic pain path-
ways (Xanthos and Sandkuhler, 2014). Nevertheless, the number
of microglia in the dorsal horn did not differ in GPR84 null mice
compared with WT littermates, nor could we see any difference
in the degree of p-p38, known to be critical formicroglial–neuron
interactions under neuropathic conditions.Dissociation between
microglia and their contribution to behavioral hypersensitivity in
animal models of peripheral neuropathy have been documented
previously (Colburn et al., 1997; Hashizume et al., 2000;Winkel-
stein and DeLeo, 2002; Shi et al., 2011). However, although we
were unable to identify microglial involvement, our analysis was
limited to gross immunophenotypic differences; thus, we cannot
rule out a potential contribution of these cells. Furthermore, in
contrast to our findings, a recent study demonstrated a beneficial
role ofGPR84 in amousemodel of Alzheimer’s disease (AD). The
authors showed that GPR84 KO mice exhibited accelerated cog-
nitive decline that correlated with reduced microgliosis, hence
indicating that microglial recruitment is protective in amyloid
pathology (Audoy-Re´mus et al., 2015). Evidence of microgliosis
has been demonstrated in a number of different neurodegenera-
tive diseases (Parkinson’s disease, multiple sclerosis, and amyo-
trophic laterals sclerosis) including AD, as well as other types of
neurological disorders (stroke, inflammation, and epilepsy). This
response is generally believed to have detrimental effects, and it
has not been until recently that more studies have begun to take
into account both the harmful and protective effects of these
multitalented cells. As a result, it remains unclear whethermicro-
glia activation is a causative (“bad for”) or reactive (“good for”)
factor in disease pathology.
Currently, the signaling pathway of GPR84 is unknown. In
any case, considering that its expression is highly regulated by
LPS and other stimulators of the NF-B pathway (IL-1 and
TNF-; Bouchard et al., 2007), it is plausible that it shares signal-
ing pathways similar to that of chemokine receptors. The endog-
enous ligand also remains unknown, but of course, it too is likely
to have an interesting biology and be important in pain process-
ing. Some data suggest that short-chain fatty acids can activate
the receptor, and thesemay turn out to be the endogenous ligand.
Whatever the actual ligand is, we postulate that, under patholog-
ical conditions, GPR84 can be activated to evoke the release of
proinflammatory mediators that contribute to pro-nociceptive
signaling.
In conclusion, our findings point toward a peripherally driven
role for GPR84 signaling in the context of neuropathic pain. The
ability of GPR84 to induce pain hypersensitivity may provide
scope for the modulation of peripheral macrophage activation
and hence the alleviation of pain. We believe that the specific
immune cell expression and proinflammatory profile warrants
GPR84 as an exciting, new, non-neuronal target for the treatment
of chronic pain.
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